Amgen Inc. (NASDAQ:AMGN) is Steigerwald Gordon & Koch Inc.’s 7th Largest Position

Steigerwald Gordon & Koch Inc. boosted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 53,432 shares of the medical research company’s stock after acquiring an additional 153 shares during the period. Amgen accounts for 3.2% of Steigerwald Gordon & Koch Inc.’s portfolio, making the stock its 7th largest holding. Steigerwald Gordon & Koch Inc.’s holdings in Amgen were worth $13,580,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Pure Financial Advisors Inc. lifted its holdings in shares of Amgen by 2.8% in the 2nd quarter. Pure Financial Advisors Inc. now owns 1,469 shares of the medical research company’s stock worth $346,000 after acquiring an additional 40 shares during the last quarter. Carroll Financial Associates Inc. lifted its holdings in shares of Amgen by 0.5% in the 3rd quarter. Carroll Financial Associates Inc. now owns 7,574 shares of the medical research company’s stock worth $1,925,000 after acquiring an additional 41 shares during the last quarter. Price Wealth LLC lifted its holdings in shares of Amgen by 42.9% in the 2nd quarter. Price Wealth LLC now owns 140 shares of the medical research company’s stock worth $33,000 after acquiring an additional 42 shares during the last quarter. FCG Advisors LLC lifted its holdings in shares of Amgen by 3.8% in the 2nd quarter. FCG Advisors LLC now owns 1,162 shares of the medical research company’s stock worth $274,000 after acquiring an additional 42 shares during the last quarter. Finally, AFT Forsyth AND Company Inc. lifted its holdings in shares of Amgen by 1.0% in the 2nd quarter. AFT Forsyth AND Company Inc. now owns 4,465 shares of the medical research company’s stock worth $1,053,000 after acquiring an additional 45 shares during the last quarter. 75.23% of the stock is owned by institutional investors.

AMGN has been the subject of several analyst reports. Credit Suisse Group restated a “buy” rating on shares of Amgen in a report on Wednesday, July 29th. SVB Leerink lifted their price objective on shares of Amgen from $253.00 to $261.00 and gave the company a “market perform” rating in a report on Wednesday, July 29th. Barclays lifted their price objective on shares of Amgen from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Raymond James reiterated a “market perform” rating on shares of Amgen in a report on Tuesday, October 6th. Finally, Morgan Stanley decreased their price objective on shares of Amgen from $281.00 to $273.00 and set an “overweight” rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and fifteen have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $255.08.

Shares of Amgen stock opened at $235.72 on Friday. The firm’s 50 day moving average price is $246.43 and its 200-day moving average price is $237.88. The company has a quick ratio of 1.81, a current ratio of 2.18 and a debt-to-equity ratio of 3.20. Amgen Inc. has a 52-week low of $177.05 and a 52-week high of $264.97. The company has a market cap of $138.06 billion, a P/E ratio of 19.26, a PEG ratio of 2.11 and a beta of 0.81.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.81 by $0.44. Amgen had a net margin of 30.04% and a return on equity of 91.98%. The firm had revenue of $6.21 billion for the quarter, compared to the consensus estimate of $6.19 billion. During the same quarter in the previous year, the firm earned $3.97 EPS. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. As a group, equities research analysts forecast that Amgen Inc. will post 15.66 EPS for the current fiscal year.

In other Amgen news, Director Ronald D. Sugar sold 1,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $241.02, for a total value of $241,020.00. Also, Director R Sanders Williams sold 250 shares of Amgen stock in a transaction on Friday, August 7th. The stock was sold at an average price of $242.95, for a total transaction of $60,737.50. Following the sale, the director now owns 5,159 shares of the company’s stock, valued at $1,253,379.05. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,250 shares of company stock worth $561,548. Insiders own 0.36% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.

Read More: Understanding the two types of arbitrage

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.